Experimental HIV Vaccine Shows Promising Results in Early Clinical Trials

The candidate HIV vaccine showed positive results in the early stages, stimulating a critical component of the human immune response in 97% of vaccine recipients.

A small phase 1 trial tested a vaccine made from a modified version of a protein found in HIV.

An early-stage HIV vaccine is positive results. If it works it will first successful HIV vaccine after almost 40 years of research. https://t.co/oXBxcRCoJk

— Health Insider (@HealthInsider) December 1, 2022

This particle is designed to prepare the body to produce broad-spectrum neutralizing antibodies (bnAbs), which are thought to be necessary to build immunity against HIV.

A broad neutralizing antibody (bnAb) recognizes a wide range of HIV subtypes, which is necessary to confer immunity because HIV often mutates.

Just out @ScienceMagazine
Progress towards an HIV vaccine through germline targetinghttps://t.co/Dyxe8ClbTN
according to my @scrippsresearch colleague Bill Schiff and staffhttps://t.co/hX049msy2x
on @PennyMo70026063 and/ @ScienceVisualsrice.twitter.com/nAhYFG7MSh

— Eric Topol (@EricTopol) December 1, 2022

HIV vaccine development Still remains one of largest biological challenges of generation’.

On the #International AIDS Day, @imperialcollege research how en international cooperation – of what oxford key partner – boosted HIV vaccine research. ⬇️https://t.co/nnkS9aMAFi

– University of Oxford (@UniofOxford) December 1, 2022

According to researchers at the Scripps Research Center, Fred Hutchinson Cancer Center, the National Institutes of Health and other institutions in the United States and Sweden, 48 participants received either the vaccine called eOD-GT8 60mer or a placebo, and 35 of 36 people who received the vaccine candidate showed activation eOD-GT8 60mer B cells that neutralize antibodies that may be the first step towards immunity.

HIV vaccine development needs a raise #International AIDS Dayhttps://t.co/bbr4ti3QqNrice.twitter.com/SudYek4zzK

— Natural Medicine (@NatureMedicine) December 1, 2022

In essence, the essence of the technology is to train the immune system to recognize a wide range of naturally occurring HIV subtypes, said William Schiff, co-author of the study and professor in the Department of Immunology and Microbiology at the Scripps Research Center.

No serious side effects were reported in the phase 1 study. Other side effects, such as pain at the injection site or headache, were mild to moderate and resolved within 1 to 2 days.

In fact, the researchers announced these findings, which were published in the academic journal Science on December 1, 2022, World AIDS Day, for the first time in 2021 at a virtual conference hosted by the International AIDS Society on HIV Research for Prevention.

Researchers have been trying to create an HIV vaccine for nearly 40 years.

Vaccination against HIV is notoriously difficult, and this is partly due to HIV’s propensity to mutate. By developing and changing rapidly, it can elude the immune system, making it difficult to identify.

In addition, almost no one has ever been cured of HIV infection, except in a few high-profile cases. This means that we do not know which types of immune cells in the body can actually protect against infection.

In theory, this vaccine will be the first in a series of multiple doses, each using a particle of HIV to train the immune system to fight it.

As the dosage is increased, eOD-GT8 60mer induces the production of broadly neutralizing antibodies by targeting and stimulating the appropriate antibody-producing cells.

“It’s kind of a whole new way of looking at creating a vaccine,” Schiff said.

Source: Business Insider